2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

Ann Oncol. 2014 Aug;25(8):1475-84. doi: 10.1093/annonc/mdu123. Epub 2014 Mar 25.


To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on first line/second and further lines of treatment in advanced disease.

Keywords: ESMO; consensus; first line; further lines; non-small-cell lung cancer; second line.

Publication types

  • Consensus Development Conference
  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Chemotherapy, Adjuvant* / methods
  • Chemotherapy, Adjuvant* / standards
  • Chemotherapy, Adjuvant* / statistics & numerical data
  • Cisplatin / administration & dosage
  • Combined Modality Therapy / methods
  • Combined Modality Therapy / standards
  • Combined Modality Therapy / statistics & numerical data
  • Consensus
  • Drug Substitution / methods
  • Drug Substitution / standards
  • Humans
  • Lung Neoplasms / drug therapy*
  • Maintenance Chemotherapy / standards
  • Maintenance Chemotherapy / statistics & numerical data
  • Neoadjuvant Therapy* / methods
  • Neoadjuvant Therapy* / standards
  • Neoadjuvant Therapy* / statistics & numerical data


  • Angiogenesis Inhibitors
  • Carboplatin
  • Cisplatin